Core Viewpoint - MicroTech Medical-B (02235) has seen a stock increase of over 4%, currently trading at 8.06 HKD, following the approval of its core product, the Equil patch insulin pump, for use in children and adolescents aged 3-17 years with diabetes, expanding its market reach significantly [1][1][1] Group 1: Product Approval and Market Expansion - The National Medical Products Administration (NMPA) has approved the Equil patch insulin pump for pediatric use, which previously was only available for adult diabetes patients [1][1] - This approval provides a new treatment option for millions of children and adolescents with diabetes in China [1][1] Group 2: Clinical Trials and Efficacy - The clinical trials for this indication were led by the Children's Hospital affiliated with Zhejiang University School of Medicine, in collaboration with six top children's hospitals across the country [1][1] - The trials demonstrated the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1][1] Group 3: Product Advantages - The patch insulin pump offers several advantages over traditional tube-based insulin pumps, including more precise and safe insulin delivery, ease of use, cost-effectiveness, enhanced privacy, and elimination of issues such as tube blockage and tangling [1][1][1]
微泰医疗-B涨超4% Equil贴敷式胰岛素泵儿童及青少年适应症获批